作为可调节的交付平台的两性块共聚物纳米结构:未来药物产品开发的前景和框架
Gaurav Sinsinbar1, Anivind Kaur Bindra1, Shaoqiong Liu1
1ACM Biolabs Pte Ltd., 71 Nanyang Drive, #02M-02, NTU Innovation Center, Singapore 638075, Singapore.
Biomacromolecules
|January 19, 2024
概括
聚合体,一种纳米配方,提供有前途的药物输送,但需要进一步开发商业化. 解决目前的局限性将使有效药物成分 (API) 的先进,有针对性和持续的交付成为可能.
科学领域:
- 纳米技术纳米技术
- 聚合物科学 聚合物科学
- 制药科学 制药科学
背景情况:
- 纳米配方旨在针对性,持续性和有效地提供活性药物成分 (API).
- 由于API固有的化学和结构性质,加载和交付API面临着挑战.
- 基于脂质的系统在API交付方面存在局限性.
研究的目的:
- 突出聚合物体作为可调节的API交付平台的潜力.
- 讨论聚合体相对于基于脂质的系统的优势.
- 确定商业化聚合物技术的局限性和发展领域.
主要方法:
- 对聚合体和API交付现有文献的审查.
- 在纳米配方中分析两类块共聚物 (ABCP) 的特性.
- 使用聚合体的COVID增强疫苗 (ACM-001) 的案例研究.
主要成果:
- 聚合物体显示出作为多功能API交付平台的重大承诺.
- 聚合体比传统的基于脂质的输送系统具有优势.
- 使用聚合体的COVID助推疫苗已成功完成I期临床试验.
结论:
- 需要进一步开发以克服聚合物技术的局限性.
- 解决这些局限性对于将基于聚合体的交付从概念转化为商业产品至关重要.
- 聚合体为先进的药物输送系统提供了可行的未来.
相关概念视频
Drug Delivery: Overview
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


